An increased risk was observed for any CVD (HR = 1.30; 95% CI = 1.04‐1.61; I2 = 44%; Figure 1A), AMI (HR = 1.63; 95% CI = 1.09‐2.43; I2 = 0%; Figure 1B) and arrhythmia (HR = 1.74; 95% CI = 1.30‐2.32; I2 = 0%; Figure 1C) for men on GnRH antagonists with a history of CVD. This evidence concerns the gene GNRH1 and Arrhythmia.